medRxiv · Nov 20, 2026
Prevalence of sarcopenia and frailty in mobility-limited older adults: the cross-sectional BIOFRAIL cohort study
By Hansen P, Nygaard H, Kamper RS et al.
Abstract Background: Sarcopenia and frailty pose considerable risks to older adults due to their close association with reduced physical performance, increased risks of falls, and mortality. Despite this, knowledge about the prevalence in mobility-limited older adults remains scarce. Therefore, we aimed to identify the prevalence and co-prevalence of sarcopenia and frailty in mobility-limited older adults. Methods: This cross-sectional study included patients aged [≥]65 years referred to a geriatric outpatient clinic for fall assessment. Sarcopenia risk was screened using SARC-F and defined according to the European Working Group on Sarcopenia in Older People criteria; frailty was evaluated using the Clinical Frailty Scale. Muscle strength was assessed by handgrip strength and the 30-second sit-to-stand test. Skeletal muscle index was determined using bioelectrical impedance analysis (Inbody770). Gait speed was assessed over 6 meters. Results: A total of 375 patients (mean age 79.7 {+/-} 6.1 years; 65% female) were included, with 28.0% demonstrating low HGS and 36.8% showing low STS performance, while only 13.9% demonstrated concurrent impairments in both tests. Low SMI was observed in 25.1% of the patients. The prevalence of sarcopenia was 14.1%, frailty 23.7%, and their co-prevalence 7.2%. Conclusions: In mobility-limited older adults referred for fall assessment, sarcopenia and frailty were common conditions showing only limited overlap. The low co-prevalence between HGS and STS underscores the importance of using multiple strength assessments, while the substantial prevalence of low muscle mass highlights the need for routine muscle mass evaluation regardless of muscle strength status. Trial registration: NCT05795556